Physician profile
Vineet Choudhry
NPI 1265659106
$851,497.75
in general payments reported to CMS, 2019-2025
26 companies · $194K in 2025
The $194K reported for 2025 was more than what 99% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63K · 2020: $68K · 2021: $106K · 2022: $133K · 2023: $121K · 2024: $167K · 2025: $194K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $375K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $62K · Travel and Lodging: $32K · Food and Beverage: $13K · Gift: $14.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $375,200.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $61,500.00 |
| Travel and Lodging | $31,923.88 |
| Food and Beverage | $13,033.40 |
| Gift | $14.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $847,616.17 | 2019-2025 | Da Vinci Surgical System, Da Vinci Sp |
| Davol INC. | $1,277.26 | 2020-2025 | Phasix Mesh, Arista |
| W. L. Gore & Associates, INC. | $472.93 | 2020 | |
| Becton, Dickinson and Company | $421.51 | 2023-2024 | Phasix Mesh |
| Conmed Corporation | $321.00 | 2019-2023 | Airseal |
| Medtronic, INC. | $285.83 | 2021-2024 | Progrip |
| Baxter Healthcare | $253.91 | 2019-2024 | Tisseel |
| Smith+Nephew, INC. | $163.04 | 2019-2025 | Versajet |
| Ethicon US, LLC | $105.28 | 2019-2025 | Ethicon |
| Tela Bio, INC. | $87.86 | 2019-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Thd America, INC. | $76.15 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.57 | 2020-2022 | |
| Integra Lifesciences Corporation | $62.24 | 2022-2024 | Integra, Integra Dermal Regeneration Template, Omnigraft |
| Amgen INC. | $56.54 | 2023-2024 | Enbrel, Otezla, Tavneos |
| Ucb, INC. | $41.41 | 2024 | Cimzia, Bimzelx |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $35.36 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Bioptics, INC. | $29.30 | 2020 | |
| Acera Surgical, INC. | $20.09 | 2024 | Restrata Wound Matrix |
| Radius Health, INC. | $18.22 | 2024 | Tymlos |
| Dilon Technologies, INC. | $17.17 | 2024 | Hemoblast Bellows |
| Myriad Genetic Laboratories, INC. | $15.51 | 2021 | |
| Lsi Solutions INC | $15.38 | 2023 | Ti Knot |
| Acell, INC. | $15.15 | 2019 | |
| Janssen Biotech, INC. | $14.60 | 2019 | |
| Asensus Surgical, INC. | $13.27 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vineet Choudhry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.